WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012115789) RECURRENT SPOP MUTATIONS IN PROSTATE CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/115789    International Application No.:    PCT/US2012/024475
Publication Date: 30.08.2012 International Filing Date: 09.02.2012
IPC:
C12Q 1/68 (2006.01), C12N 15/11 (2006.01)
Applicants: CORNELL UNIVERSITY [US/US]; Cornell Center for Technology, Enterprise & Commercialization 395 Pine Tree Road Suite 310 Ithaca, New York 14850 (US) (For All Designated States Except US).
RUBIN, Mark A. [US/US]; (US) (For US Only).
BARBIERI, Christopher [US/US]; (US) (For US Only)
Inventors: RUBIN, Mark A.; (US).
BARBIERI, Christopher; (US)
Agent: GROLZ, Edward W.; Scully, Scott, Murphy & Presser 400 Garden City Plaza Suite 300 Garden City, New York 11530 (US)
Priority Data:
61/446,255 24.02.2011 US
61/467,735 25.03.2011 US
Title (EN) RECURRENT SPOP MUTATIONS IN PROSTATE CANCER
(FR) MUTATIONS SPOP RÉCURRENTES DANS LE CANCER DE LA PROSTATE
Abstract: front page image
(EN)The invention relates generally to new prostate cancer markers, and particularly to a class of cancer marked by the presence of missense mutations in SPOP, an E3 ubiquitin ligase component. The invention provides methods and materials for detecting and diagnosing prostate cancer by detecting these mutations and may be useful in predicting disease progression and response to therapy.
(FR)De manière générale, cette invention concerne de nouveaux marqueurs du cancer de la prostate, et en particulier, une classe de cancers marqués par la présence de mutations faux-sens dans SPOP, un composant de l'ubiquitine-ligase E3. Cette invention concerne des méthodes et des matériaux pour dépister et diagnostiquer le cancer de la prostate par détection de ces mutations et peut être utile pour prédire l'évolution de la maladie et sa réponse à la thérapie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)